Fig. 2.

Changes in iron-related parameters (Period 1). (a) Correction group, Period 1; (b) conversion group, Period 1. Each point indicates the median value on each observation day in each treatment arm; bars indicate quartile deviations. Post hoc analysis was performed only for changes in Week 6, which were compared between the placebo arm and each enarodustat arm using the Wilcoxon rank sum test (significance level: 5%, 2-sided). Adjustment for multiplicity was not performed. * p < 0.05, ** p < 0.0001. BL, baseline; TIBC, total iron-binding capacity; TSAT, transferrin saturation.